Curis(CRIS) - 2024 Q3 - Quarterly Results

Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2024 Business Update Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended September 30, 2024. "We continue to make excellent progress across our clinical pro ...